Defender’s Scopolamine Nasal Gel Secures Pivotal Win In Motion Sickness
Could Challenge Bayer’s Patch
Executive Summary
The US firm’s nasal gel formulation of the anticholinergic compound has succeeded in a second Phase III trial, bringing Defender closer to entering a market dominated by Bayer’s Transderm Scop.